Biosimilars in the management of neutropenia: focus on filgrastim
Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Abstract: Advanc...
Guardado en:
Autores principales: | Caselli D, Cesaro S, Aricò M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4d89cc2f957e45c99acdc3cadddf2ed7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini F, et al.
Publicado: (2018) -
Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America
por: Mendoza-Macedo,Karina, et al.
Publicado: (2016) -
Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser JRP, et al.
Publicado: (2017) -
The importance of the prevention of treatment induced neutropenia in patients with malignant neoplasms of the head and neck
por: Editorial Board
Publicado: (2021) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia R, et al.
Publicado: (2016)